Form 4 for TXG 10x Genomics, Inc.
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001610717-24-000058 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-02-13 | 2024-02-09 | TXG | Saxonov Serge | CEO, Dir | S - Sale | $49.53 | -1,000 | 855.4K | -0.1% | -$49.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-02-09 | S | D | 1,000 | $49.53 | 855,381 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $49.50 to $49.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |